BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-347@pharmaconomics
DTSTAMP:20260707T034219Z
DTSTART;VALUE=DATE:20260530
DTEND;VALUE=DATE:20260531
SUMMARY:COGT Phase 3 — bezuclastinib
DESCRIPTION:Phase 3 trial results for bezuclastinib in Gastrointestinal Stromal Tumor are due May 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/347
URL:https://www.pharmaconomics.com/e/347
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:COGT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR